| Literature DB >> 34267371 |
Bradley D Weaver1, Christina M Smith1, Edward J Grow1, Jingtao Guo1,2, Paula Stein3, Sean C Shadle1, Peter G Hendrickson1, Nicholas E Johnson4, Russell J Butterfield4, Roberta Menafra5, Susan L Kloet5, Silvère M van der Maarel6, Carmen J Williams3, Bradley R Cairns7.
Abstract
In mammalian embryos, proper zygotic genome activation (ZGA) underlies totipotent development. Double homeobox (DUX)-family factors participate in ZGA, and mouse Dux is required for forming cultured two-cell (2C)-like cells. Remarkably, in mouse embryonic stem cells, Dux is activated by the tumor suppressor p53, and Dux expression promotes differentiation into expanded-fate cell types. Long-read sequencing and assembly of the mouse Dux locus reveals its complex chromatin regulation including putative positive and negative feedback loops. We show that the p53-DUX/DUX4 regulatory axis is conserved in humans. Furthermore, we demonstrate that cells derived from patients with facioscapulohumeral muscular dystrophy (FSHD) activate human DUX4 during p53 signaling via a p53-binding site in a primate-specific subtelomeric long terminal repeat (LTR)10C element. In summary, our work shows that p53 activation convergently evolved to couple p53 to Dux/DUX4 activation in embryonic stem cells, embryos and cells from patients with FSHD, potentially uniting the developmental and disease regulation of DUX-family factors and identifying evidence-based therapeutic opportunities for FSHD.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34267371 PMCID: PMC8513633 DOI: 10.1038/s41588-021-00893-0
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 38.330